Carl Zeiss Meditec AG
AFX: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€53.00 | Vrjyrbn | Dmzwnkqc |
Carl Zeiss Ends Year on Mixed Note; Maintaining Fair Value Estimate
Narrow-moat Carl Zeiss ended its fiscal year with mixed results. Despite strong top-line growth of 15%, operating margins fell slightly. While other medical device manufacturers look primed to rebound after short-term macro headwinds pass, Zeiss seems to have some wind at its back already and less of a runway. We maintain our fair value estimate of EUR 69 per share.